An orally bioavailable KAT6A and 6B inhibitor that selectively inhibits the catalytic activity of KAT6A and KAT6B was recently shown to elicit on-target antitumor activity in vivo in ER+ breast cancer and other cancer types in preclinical studies13. Here, KAT6B is linked to cancer.